Quest and LabCorp recently highlighted increased compensation costs while other industry observers have seen salaries rising for specialties like molecular.
The company said that it experienced a breach of an internal data system used by its integrated oncology business and that it is investigating the incident.
A pair of lawyers familiar with the case said that while ACLA might not win the legal battle, its lawsuit could aid efforts to get a legal fix to the law.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
The firm is offering total consideration of $1,018.36 per $1,000 for notes tendered by Dec. 2, which includes an early tender premium of $30 per $1,000.
